Corporate Profile
| Company name | AskAt Inc. |
|---|---|
| Locations |
|
| Establishment | January 7, 2013 |
| Capital | 87,000,000 yen |
| President | Akihiro Furuta |
History
| January 2013 | Is launched with capital of 1,000,000 yen as a wholly owned subsidiary of RaQualia Inc. Acquires the following compounds as intellectual property: ・EP4 antagonist / AAT-007, AAT-008 ・5-HT4 partial agonist / AAT-009 ・COX-2 inhibitor / AAT-076 President Shinichi Koizumi |
|---|---|
| June 2013 | Acquires management rights from RaQualia Inc. |
| April 2015 | Akihiro Furuta becomes president |
| May 2015 | Becomes fully independent of RaQualia |
| June 2015 | Issues new shares to third parties (capital 9,750,000 yen) |
| September 2015 | Issues new shares to third parties (capital 17,000,000 yen) |
| November 2015 | Acquires CB2 antagonist intellectual property from RaQualia Inc. |
| January 2016 | Concludes license agreement with RMX for AAT-076 and AAT-007 in China. Issues new shares to third parties (capital 37,000,000 yen) |
| March 2016 | Issues new shares to third parties (capital 62,000,000 yen) |
| December 2016 | Concludes license agreement with Ningbo Tai Kang for AAT-007 in China. |
| May 2017 | Issues new shares to third parties (capital 87,000,000 yen) |
| December 2017 | Concludes worldwide license agreement (excluding China and Taiwan) with Arrys Therapeutics for AAT-007 and AAT-008 |
| February 2018 | Concludes license agreement with NewBay Medical Technology for AAT-008 in China and Taiwan Concludes worldwide license agreement with Aratana Therapeutics for AAT-008 in animal health |
